guest ::
| Home > Publications Database > Linking higher amyloid beta 1-38 (Aβ(1-38)) levels to reduced Alzheimer's disease progression risk. > print |
| Home > Publications Database > Linking higher amyloid beta 1-38 (Aβ(1-38)) levels to reduced Alzheimer's disease progression risk. > print |
| 001 | 277323 | ||
| 005 | 20250323000921.0 | ||
| 024 | 7 | _ | |a 10.1002/alz.14545 |2 doi |
| 024 | 7 | _ | |a pmid:39868793 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC11863357 |2 pmc |
| 024 | 7 | _ | |a 1552-5260 |2 ISSN |
| 024 | 7 | _ | |a 1552-5279 |2 ISSN |
| 024 | 7 | _ | |a altmetric:173681338 |2 altmetric |
| 037 | _ | _ | |a DZNE-2025-00385 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Schneider, Luisa Sophie |0 P:(DE-2719)9002878 |b 0 |
| 245 | _ | _ | |a Linking higher amyloid beta 1-38 (Aβ(1-38)) levels to reduced Alzheimer's disease progression risk. |
| 260 | _ | _ | |a Hoboken, NJ |c 2025 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1740669423_17975 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The beneficial effects of amyloid beta 1-38, or Aβ(1-38), on Alzheimer's disease (AD) progression in humans in vivo remain controversial. We investigated AD patients' cerebrospinal fluid (CSF) Aβ(1-38) and AD progression.Cognitive function and diagnostic change were assessed annually for 3 years in 177 Aβ-positive participants with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia from the German Center for Neurodegenerative Diseases (DZNE) longitudinal cognitive impairment and dementia study (DELCODE) cohort using the Mini-Mental State Examination (MMSE), Preclinical Alzheimer's Cognitive Composite (PACC), Clinical Dementia Rating (CDR), and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria. Mixed linear and Cox regression analyses were conducted. CSF was collected at baseline.Higher Aβ(1-38) levels were associated with slower PACC (p = 0.001) and slower CDR Sum of Boxes (CDR-SB) (p = 0.002) but not MMSE decline. Including Aβ(1-40) beyond Aβ(1-38) in the model confirmed an association of Aβ(1-38) with slower PACC decline (p = 0.005), but not with CDR-SB or MMSE decline. In addition, higher Aβ(1-38) baseline levels were associated with a reduced dementia conversion risk.Further research is needed to understand the role of Aβ(1-38) in AD and its potential for future therapeutic strategies.This study not only replicates but also extends the existing findings on the role of Aβ(1-38) (amyloid beta 1-38) in Alzheimer's disease (AD) in humans in vivo. Higher baseline Aβ(1-38) levels were associated with a decreased risk of conversion to AD dementia in subjective cognitive decline (SCD) and mild cognitive impairment (MCI). Different linear-mixed regression models suggest an association between higher Aβ(1-38) baseline levels and slower Preclinical Alzheimer's Cognitive Composite (PACC) and Clinical Dementia Rating Sum of Boxes (CDR-SB) decline. Including Aβ(1-40) beyond Aβ(1-38) in the model confirmed a link between Aβ(1-38) and PACC decline, but showed no association of Aβ(1-38) on CDR-SB and Mini-Mental State Examination (MMSE) decline. The impact of short Aβ isoforms in AD progression might have been under-investigated These findings underscore the urgent need for additional research on the role of these shorter Aβ peptides in AD, as they may hold key insights for future therapeutic strategies. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a AD conversion risk |2 Other |
| 650 | _ | 7 | |a Alzheimer's disease |2 Other |
| 650 | _ | 7 | |a Aβ(1‐38) |2 Other |
| 650 | _ | 7 | |a cerebrospinal fluid |2 Other |
| 650 | _ | 7 | |a cognitive decline |2 Other |
| 650 | _ | 7 | |a neurotoxicity |2 Other |
| 650 | _ | 7 | |a protective factor |2 Other |
| 650 | _ | 7 | |a shorter Aβ peptides |2 Other |
| 650 | _ | 7 | |a Amyloid beta-Peptides |2 NLM Chemicals |
| 650 | _ | 7 | |a Peptide Fragments |2 NLM Chemicals |
| 650 | _ | 7 | |a amyloid beta-protein (1-38) |2 NLM Chemicals |
| 650 | _ | 7 | |a Biomarkers |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Amyloid beta-Peptides: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Disease Progression |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Peptide Fragments: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Cognitive Dysfunction: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Longitudinal Studies |2 MeSH |
| 650 | _ | 2 | |a Mental Status and Dementia Tests |2 MeSH |
| 650 | _ | 2 | |a Biomarkers: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Aged, 80 and over |2 MeSH |
| 650 | _ | 2 | |a Neuropsychological Tests: statistics & numerical data |2 MeSH |
| 700 | 1 | _ | |a Freiesleben, Silka Dawn |0 P:(DE-2719)2812392 |b 1 |u dzne |
| 700 | 1 | _ | |a van Breukelen, Gerard |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Wang, Xiao |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Brosseron, Frederic |0 P:(DE-2719)2810593 |b 4 |u dzne |
| 700 | 1 | _ | |a Heneka, Michael T |0 P:(DE-2719)2000008 |b 5 |
| 700 | 1 | _ | |a Teipel, Stefan |0 P:(DE-2719)2000026 |b 6 |u dzne |
| 700 | 1 | _ | |a Kleineidam, Luca |0 P:(DE-2719)2812139 |b 7 |u dzne |
| 700 | 1 | _ | |a Stark, Melina |0 P:(DE-2719)9001773 |b 8 |u dzne |
| 700 | 1 | _ | |a Roy-Kluth, Nina |0 P:(DE-2719)2812341 |b 9 |u dzne |
| 700 | 1 | _ | |a Wagner, Michael |0 P:(DE-2719)2000057 |b 10 |u dzne |
| 700 | 1 | _ | |a Spottke, Annika |0 P:(DE-2719)2811324 |b 11 |u dzne |
| 700 | 1 | _ | |a Schmid, Matthias |0 P:(DE-2719)2811245 |b 12 |u dzne |
| 700 | 1 | _ | |a Roeske, Sandra |0 P:(DE-2719)2810395 |b 13 |u dzne |
| 700 | 1 | _ | |a Laske, Christoph |0 P:(DE-2719)2000055 |b 14 |u dzne |
| 700 | 1 | _ | |a Munk, Matthias H |0 P:(DE-2719)9001516 |b 15 |u dzne |
| 700 | 1 | _ | |a Perneczky, Robert |0 P:(DE-2719)2812234 |b 16 |u dzne |
| 700 | 1 | _ | |a Rauchmann, Boris Stephan |0 P:(DE-2719)9001808 |b 17 |u dzne |
| 700 | 1 | _ | |a Buerger, Katharina |0 P:(DE-2719)2811351 |b 18 |u dzne |
| 700 | 1 | _ | |a Janowitz, Daniel |0 P:(DE-2719)9002557 |b 19 |u dzne |
| 700 | 1 | _ | |a Düzel, Emrah |0 P:(DE-2719)2000005 |b 20 |u dzne |
| 700 | 1 | _ | |a Glanz, Wenzel |0 P:(DE-2719)2811614 |b 21 |u dzne |
| 700 | 1 | _ | |a Jessen, Frank |0 P:(DE-2719)2000032 |b 22 |u dzne |
| 700 | 1 | _ | |a Rostamzadeh, Ayda |0 P:(DE-HGF)0 |b 23 |
| 700 | 1 | _ | |a Wiltfang, Jens |0 P:(DE-2719)2811317 |b 24 |u dzne |
| 700 | 1 | _ | |a Bartels, Claudia |0 P:(DE-2719)9000444 |b 25 |
| 700 | 1 | _ | |a Kilimann, Ingo |0 P:(DE-2719)2810394 |b 26 |u dzne |
| 700 | 1 | _ | |a Schneider, Anja |0 P:(DE-2719)2812035 |b 27 |u dzne |
| 700 | 1 | _ | |a Fliessbach, Klaus |0 P:(DE-2719)2811326 |b 28 |u dzne |
| 700 | 1 | _ | |a Priller, Josef |0 P:(DE-2719)2811122 |b 29 |u dzne |
| 700 | 1 | _ | |a Spruth, Eike Jakob |0 P:(DE-2719)2812446 |b 30 |
| 700 | 1 | _ | |a Hellmann-Regen, Julian |0 P:(DE-2719)9003016 |b 31 |u dzne |
| 700 | 1 | _ | |a Peters, Oliver |0 P:(DE-2719)2811024 |b 32 |e Last author |u dzne |
| 773 | _ | _ | |a 10.1002/alz.14545 |g Vol. 21, no. 2, p. e14545 |0 PERI:(DE-600)2201940-6 |n 2 |p e14545 |t Alzheimer's and dementia |v 21 |y 2025 |x 1552-5260 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/277323/files/DZNE-2025-00385.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/277323/files/DZNE-2025-00385.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:277323 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)9002878 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-2719)2812392 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 4 |6 P:(DE-2719)2810593 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 6 |6 P:(DE-2719)2000026 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 7 |6 P:(DE-2719)2812139 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 8 |6 P:(DE-2719)9001773 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 9 |6 P:(DE-2719)2812341 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 10 |6 P:(DE-2719)2000057 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 11 |6 P:(DE-2719)2811324 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)2811245 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 13 |6 P:(DE-2719)2810395 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 14 |6 P:(DE-2719)2000055 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 15 |6 P:(DE-2719)9001516 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 16 |6 P:(DE-2719)2812234 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 17 |6 P:(DE-2719)9001808 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 18 |6 P:(DE-2719)2811351 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 19 |6 P:(DE-2719)9002557 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 20 |6 P:(DE-2719)2000005 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 21 |6 P:(DE-2719)2811614 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 22 |6 P:(DE-2719)2000032 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 24 |6 P:(DE-2719)2811317 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 26 |6 P:(DE-2719)2810394 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 27 |6 P:(DE-2719)2812035 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 28 |6 P:(DE-2719)2811326 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 29 |6 P:(DE-2719)2811122 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 30 |6 P:(DE-2719)2812446 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 31 |6 P:(DE-2719)9003016 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 32 |6 P:(DE-2719)2811024 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-06 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2025-01-06 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-06 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-06 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-06 |
| 920 | 1 | _ | |0 I:(DE-2719)5000000 |k AG Peters |l Biomarker-Assisted Early Detection of Dementias |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1810002 |k AG Dirnagl |l Vascular Pathology |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1011201 |k AG Wagner |l Neuropsychology |x 2 |
| 920 | 1 | _ | |0 I:(DE-2719)1011103 |k AG Spottke |l Clinical Research Platform (CRP) |x 3 |
| 920 | 1 | _ | |0 I:(DE-2719)1011303 |k AG Heneka |l Neuroinflammation, Biomarker |x 4 |
| 920 | 1 | _ | |0 I:(DE-2719)1013028 |k AG Schmid Bonn |l Mathematics, statistics and informatics methods for support of population studies and clinical research |x 5 |
| 920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser |l Parkinson Genetics |x 6 |
| 920 | 1 | _ | |0 I:(DE-2719)5000022 |k AG Dichgans |l Vascular Cognitive Impairment & Post-Stroke Dementia |x 7 |
| 920 | 1 | _ | |0 I:(DE-2719)1111015 |k Clinical Research (Munich) |l Clinical Research (Munich) |x 8 |
| 920 | 1 | _ | |0 I:(DE-2719)1811005 |k AG Endres |l Interdisciplinary Dementia Research |x 9 |
| 920 | 1 | _ | |0 I:(DE-2719)5000007 |k AG Priller |l Translational Neuropsychiatry |x 10 |
| 920 | 1 | _ | |0 I:(DE-2719)1011101 |k Patient Studies (Bonn) |l Patient Studies (Bonn) |x 11 |
| 920 | 1 | _ | |0 I:(DE-2719)1410006 |k AG Wiltfang |l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases |x 12 |
| 920 | 1 | _ | |0 I:(DE-2719)1011102 |k AG Jessen |l Clinical Alzheimer’s Disease Research |x 13 |
| 920 | 1 | _ | |0 I:(DE-2719)5000006 |k AG Düzel |l Clinical Neurophysiology and Memory |x 14 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)5000000 |
| 980 | _ | _ | |a I:(DE-2719)1810002 |
| 980 | _ | _ | |a I:(DE-2719)1011201 |
| 980 | _ | _ | |a I:(DE-2719)1011103 |
| 980 | _ | _ | |a I:(DE-2719)1011303 |
| 980 | _ | _ | |a I:(DE-2719)1013028 |
| 980 | _ | _ | |a I:(DE-2719)1210000 |
| 980 | _ | _ | |a I:(DE-2719)5000022 |
| 980 | _ | _ | |a I:(DE-2719)1111015 |
| 980 | _ | _ | |a I:(DE-2719)1811005 |
| 980 | _ | _ | |a I:(DE-2719)5000007 |
| 980 | _ | _ | |a I:(DE-2719)1011101 |
| 980 | _ | _ | |a I:(DE-2719)1410006 |
| 980 | _ | _ | |a I:(DE-2719)1011102 |
| 980 | _ | _ | |a I:(DE-2719)5000006 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|